The Technical Analyst
Myomo Inc [MYO]
Exchange: AMEX Industry: Medical Devices
Myomo Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
3.68% $2.82
America/New_York / 18 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 80.33 mill |
| EPS: | -0.270 |
| P/E: | -10.44 |
| Earnings Date: | May 08, 2024 |
| SharesOutstanding: | 28.49 mill |
| Avg Daily Volume: | 0.336 mill |
| RATING 2024-04-18 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -10.44 | sector: PE 12.30 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.50x |
| Company: PE -10.44 | industry: PE 21.09 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 2.50 - 3.14 ( +/- 11.45%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-03 | Kovelman Harry | Sell | 146 | Common Stock |
| 2024-03-26 | Getz Heather C | Buy | 0 | |
| 2024-03-14 | Kirk Thomas F | Buy | 50 000 | Common Stock |
| 2024-03-11 | Henry David A | Sell | 7 774 | Common Stock |
| 2024-03-11 | Kovelman Harry | Sell | 6 590 | Common Stock |
| INSIDER POWER |
|---|
| 88.49 |
| Last 98 transactions |
| Buy: 1 844 498 | Sell: 109 952 |
Forecast:
16:00 - $2.82
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $2.82
Forecast 2: 16:00 - $2.82
Forecast 3: 16:00 - $2.82
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $2.82 (3.68% ) |
| Volume | 0.200 mill |
| Avg. Vol. | 0.336 mill |
| % of Avg. Vol | 59.63 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For MYO
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
MYO
Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. Its products are designed to help improve function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. The company sells its products to orthotics and prosthetics providers, the Veterans Health Administration, and rehabilitation hospitals, as well as through distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.
Latest Press Releases
2024-03-28 16:05:00 - Press Release
Myomo Appoints Heather Getz To Its Board Of Directors
Boston--(business wire)--myomo, inc. (nyse american: myo) ("myomo" or the "company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the appointment of heather getz as a class ii director and chair of its audit committee effective march 26, 2024, to serve until the 2025 annual meeting of stockholders. with this appointment, myomo has seven directors. ms. getz brings more than 25 ye.
2024-03-07 16:05:00 - Press Release
Myomo Reports Fourth Quarter And Full Year 2023 Financial Results
Boston--(business wire)--myomo, inc. (nyse american: myo) (“myomo” or the “company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced financial results for the three months and year ended december 31, 2023. financial and operational highlights for the fourth quarter of 2023 include the following (all comparisons are with the fourth quarter of 2022): total and product revenue was $4.
2024-03-01 08:00:00 - Press Release
Cms Posts Final Medicare Dmepos Fee Schedule Rate For The Myopro®
Boston--(business wire)--myomo, inc. (nyse american: myo) (“myomo” or the “company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that on february 29, 2024, the centers for medicare & medicaid services (cms) posted the final medicare durable medical equipment, prosthetics, orthotics, and supplies (dmepos) fee schedule payment rates for the myopro®. the final average fee sche.
2024-02-29 16:05:00 - Press Release
Myomo To Report Fourth Quarter Financial Results On March 7, 2024
Boston--(business wire)--myomo, inc. (nyse american: myo) (“myomo” or the “company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the fourth quarter and fiscal year ended december 31, 2023 on march 7, 2024. the company will host a conference call the same day, thursday march 7, 2024 at 4:30 p.m. et with prepared remarks by paul r. gudoni.
2024-01-19 16:05:00 - Press Release
Myomo Announces Closing Of $6 Million Registered Direct Offering Of Common Stock Priced At-the-market
Boston--(business wire)--myomo, inc. (nyse american: myo) (“myomo” or the “company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it has closed its previously announced registered direct offering of its common stock, priced at-the-market with certain new and existing institutional investors as well as certain insiders of the company, for the purchase and sale of 1,578,948 s.
Latest News
2024-03-10 03:00:22 - Seeking Alpha
Myomo, Inc.: In Motion To Accelerating Revenue Growth
Medicare decision created a multi-decade revenue growth opportunity. Soft Q1 guidance due to non-recurring timing issues. 2024 guidance gives only partial-year credit to reimbursement change.
2024-03-07 19:01:38 - Zacks Investment Research
Myomo, Inc. (MYO) Reports Q4 Loss, Tops Revenue Estimates
Myomo, Inc. (MYO) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.29 per share a year ago.
2023-12-20 10:31:30 - Zacks Investment Research
What Makes Myomo, Inc. (MYO) a Good Fit for 'Trend Investing'
If you are looking for stocks that are well positioned to maintain their recent uptrend, Myomo, Inc. (MYO) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
2023-12-01 13:32:58 - Seeking Alpha
Myomo: Market Severely Undervaluing Opportunity
Market undervalues MYO stock due to poor understanding of CMS process. MYO is able to generate revenues in excess of $100mm/yr. MYO valuation gap will close before February 2024, when the final CMS price is published.
2023-11-20 16:16:18 - InvestorPlace
3 Hot Penny Stocks to Buy in Q4 for Promising Potential
Penny stocks are typically companies that are trading below $5 per share. These companies are ones that can be risky to invest in.
2023-11-07 18:28:06 - Seeking Alpha
Myomo, Inc. (MYO) Q3 2023 Earnings Call Transcript
2023-08-28 09:08:27 - InvestorPlace
Why Is Myomo (MYO) Stock Down 13% Today?
Myomo (NYSEMKT: MYO ) stock is dropping on Monday after the wearable medical robotics company priced a public share offering. A press release from Myomo highlights details of its planned public offering.
2023-08-09 18:59:30 - Zacks Investment Research
Myomo, Inc. (MYO) Reports Q2 Loss, Tops Revenue Estimates
Myomo, Inc. (MYO) came out with a quarterly loss of $0.04 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.42 per share a year ago.
2023-08-09 18:19:06 - Seeking Alpha
Myomo, Inc. (MYO) Q2 2023 Earnings Call Transcript
Myomo, Inc. (NYSE:MYO ) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Kim Golodetz - Investor Relations, LHA Paul Gudonis - Chief Executive Officer Dave Henry - Chief Financial Officer Conference Call Participants Ben Haynor - Alliance Global Partners Scott Henry - ROTH Capital Anthony Vendetti - Maxim Group Edward Woo - Ascendant Capital Operator Good afternoon, and welcome to the Myomo Second Quarter 2023 Earnings Conference Call. All participants will be in a listen-only mode.
2023-07-05 12:17:20 - Zacks Investment Research
Myomo's (MYO) MyoPro Seeks CMS Classification for Medicare Cover
If this rule is finalized without any changes to reimbursement practices, Myomo's (MYO) MyoPro could be reimbursed in a lump-sum manner by CMS.